company background image
COLL

Collegium PharmaceuticalNasdaqGS:COLL Stock Report

Last Price

US$17.54

Market Cap

US$610.3m

7D

-3.3%

1Y

-25.7%

Updated

21 Jan, 2022

Data

Company Financials +
COLL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health4/6
Dividends0/6

COLL Stock Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Collegium Pharmaceutical Competitors

Viatris

NasdaqGS:VTRS

US$17.7b

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.5b

Pacira BioSciences

NasdaqGS:PCRX

US$2.9b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$1.6b

Price History & Performance

Summary of all time highs, changes and price drops for Collegium Pharmaceutical
Historical stock prices
Current Share PriceUS$17.54
52 Week HighUS$26.91
52 Week LowUS$17.22
Beta0.97
1 Month Change-6.45%
3 Month Change-16.71%
1 Year Change-25.74%
3 Year Change15.02%
5 Year Change13.90%
Change since IPO42.72%

Recent News & Updates

Oct 30
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Oct 04

Sizing Up Collegium Pharmaceuticals

Today, we revisit Collegium Pharmaceuticals for the first time since March of last year. The company is doing a good job of reducing debt and recently announced a substantial stock buyback program. A full investment analysis follows in the paragraphs below.

Shareholder Returns

COLLUS PharmaceuticalsUS Market
7D-3.3%-2.2%-4.0%
1Y-25.7%7.1%6.6%

Return vs Industry: COLL underperformed the US Pharmaceuticals industry which returned 6.7% over the past year.

Return vs Market: COLL underperformed the US Market which returned 7.7% over the past year.

Price Volatility

Is COLL's price volatile compared to industry and market?
COLL volatility
COLL Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: COLL's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002234Joe Ciaffonihttps://www.collegiumpharma.com

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.

Collegium Pharmaceutical Fundamentals Summary

How do Collegium Pharmaceutical's earnings and revenue compare to its market cap?
COLL fundamental statistics
Market CapUS$610.34m
Earnings (TTM)US$103.51m
Revenue (TTM)US$325.78m

5.9x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COLL income statement (TTM)
RevenueUS$325.78m
Cost of RevenueUS$62.35m
Gross ProfitUS$263.42m
ExpensesUS$159.91m
EarningsUS$103.51m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.97
Gross Margin80.86%
Net Profit Margin31.77%
Debt/Equity Ratio104.2%

How did COLL perform over the long term?

See historical performance and comparison

Valuation

Is Collegium Pharmaceutical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: COLL ($17.54) is trading below our estimate of fair value ($102.22)

Significantly Below Fair Value: COLL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: COLL is good value based on its PE Ratio (5.9x) compared to the US Pharmaceuticals industry average (23.1x).

PE vs Market: COLL is good value based on its PE Ratio (5.9x) compared to the US market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: COLL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: COLL is overvalued based on its PB Ratio (2.4x) compared to the US Pharmaceuticals industry average (2.2x).


Future Growth

How is Collegium Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-11.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLL's earnings are forecast to decline over the next 3 years (-11.6% per year).

Earnings vs Market: COLL's earnings are forecast to decline over the next 3 years (-11.6% per year).

High Growth Earnings: COLL's earnings are forecast to decline over the next 3 years.

Revenue vs Market: COLL's revenue (1.6% per year) is forecast to grow slower than the US market (9.3% per year).

High Growth Revenue: COLL's revenue (1.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if COLL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Collegium Pharmaceutical performed over the past 5 years?

66.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COLL has high quality earnings.

Growing Profit Margin: COLL's current net profit margins (31.8%) are higher than last year (5.7%).


Past Earnings Growth Analysis

Earnings Trend: COLL has become profitable over the past 5 years, growing earnings by 66.6% per year.

Accelerating Growth: COLL's earnings growth over the past year (488.4%) exceeds its 5-year average (66.6% per year).

Earnings vs Industry: COLL earnings growth over the past year (488.4%) exceeded the Pharmaceuticals industry 12.2%.


Return on Equity

High ROE: Whilst COLL's Return on Equity (41.22%) is outstanding, this metric is skewed due to their high level of debt.


Financial Health

How is Collegium Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: COLL's short term assets ($363.2M) exceed its short term liabilities ($269.0M).

Long Term Liabilities: COLL's short term assets ($363.2M) exceed its long term liabilities ($221.7M).


Debt to Equity History and Analysis

Debt Level: COLL's net debt to equity ratio (27.3%) is considered satisfactory.

Reducing Debt: COLL's debt to equity ratio has increased from 6.4% to 104.2% over the past 5 years.

Debt Coverage: COLL's debt is well covered by operating cash flow (34.4%).

Interest Coverage: COLL's interest payments on its debt are not well covered by EBIT (2.8x coverage).


Balance Sheet


Dividend

What is Collegium Pharmaceutical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate COLL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate COLL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if COLL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COLL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COLL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Joe Ciaffoni (50 yo)

3.5yrs

Tenure

US$6,042,639

Compensation

Mr. Joseph J. Ciaffoni, also known as Joe, has been Chief Executive Officer and Director of Collegium Pharmaceutical, Inc. since July 1, 2018 and also has been its President since July 2018. Mr. Ciaffoni s...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD2.40M).

Compensation vs Earnings: Joe's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: COLL's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: COLL's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Collegium Pharmaceutical, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Collegium Pharmaceutical, Inc.
  • Ticker: COLL
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$610.342m
  • Shares outstanding: 34.80m
  • Website: https://www.collegiumpharma.com

Number of Employees


Location

  • Collegium Pharmaceutical, Inc.
  • 100 Technology Center Drive
  • Suite 300
  • Stoughton
  • Massachusetts
  • 2072
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 00:03
End of Day Share Price2022/01/20 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.